DeepMed Research

Ildong Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-03-01

Employees: 1K

Market Cap: -

Website: http://www.ildong.com

Clinical Trials

Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Immediate release capsule(lyrica 150mg * 2/day)
Drug: sustained release tablet

First Posted Date: 2014-04-04

Last Posted Date: 2014-09-01

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 24

Registration Number: NCT02103647

Locations: 🇰🇷
Catholic medical center, Seoul, Seocho-gu, Korea, Republic of

Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Experimental drug
Drug: Lyrica
Dietary Supplement: fasted
Dietary Supplement: High fat meal

First Posted Date: 2014-04-04

Last Posted Date: 2014-09-01

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 30

Registration Number: NCT02103686

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Nateglinide/Metformin
Drug: Nateglinide
Drug: Metformin

First Posted Date: 2014-03-17

Last Posted Date: 2014-03-17

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 40

Registration Number: NCT02088918

Locations: 🇰🇷
Chungnam University Hospital, Daejeon, Korea, Republic of

A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan

Phase 1

Conditions: Healthy Volunteers

Interventions: Drug: cinidipine, valsartan

First Posted Date: 2014-03-14

Last Posted Date: 2014-03-14

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 54

Registration Number: NCT02088008

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

Phase 3

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Telmisartan 80mg
Drug: Rosuvastatin 20mg
Drug: Rosuvastatin 10mg
Drug: Placebo(for Telmisartan 80mg)
Drug: Placebo(for Rosuvastatin 10mg)
Drug: Placebo(for Rosuvastatin 20mg)

First Posted Date: 2014-03-14

Last Posted Date: 2014-03-14

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 310

Registration Number: NCT02087540

Locations: 🇰🇷
The Catholic University of Saint Mary's Hosiptal, Seoul, Korea, Republic of

Safety Study of APD-791 With Aspirin and/or Clopidogrel

Phase 1

Terminated

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Aspirin
Drug: Placebo
Drug: APD791

First Posted Date: 2014-01-13

Last Posted Date: 2019-02-15

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 16

Registration Number: NCT02034292

Phase 3 and Extensional Study of Besifovir

Phase 3

Conditions: Chronic Hepatitis B

Interventions: Drug: tenofovir 300mg
Drug: besifovir 150mg

First Posted Date: 2013-09-10

Last Posted Date: 2020-01-27

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 197

Registration Number: NCT01937806

Locations: 🇰🇷
Soonchunhyang University Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Medical Center, Seoul, Korea, Republic of
🇰🇷
Wonju Sevrerance Christian Hospital, Wonju, Kangwon-do, Korea, Republic of

and more 15 locations

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: IDP-73152 mesylate 40 mg
Drug: IDP-73152 mesylate 80 mg
Drug: IDP-73152 mesylate 160 mg
Drug: IDP-73152 mesylate 320 mg
Drug: IDP-73152 mesylate 640 mg
Drug: IDP-73152 mesylate 1280 mg
Drug: Placebo

First Posted Date: 2013-07-22

Last Posted Date: 2014-02-12

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 56

Registration Number: NCT01904318

Locations: 🇰🇷
Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of

Pharmacokinetic Study of Belviq in Adult Korean Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Belviq 10mg
Drug: Belviq 20mg
Drug: Placebo

First Posted Date: 2013-06-19

Last Posted Date: 2013-10-14

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 25

Registration Number: NCT01880502

Locations: 🇰🇷
Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of

A Drug Interaction Study of Cilnidipine and Valsartan

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: V - C+V - C
Drug: C - V - C+V
Drug: V - C - C+V
Drug: C+V - C - V
Drug: C+V - V - C
Drug: C - C+V - V

First Posted Date: 2013-04-24

Last Posted Date: 2013-10-14

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 54

Registration Number: NCT01838967

Locations: 🇰🇷
Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy